LEMTRADA (alemtuzumab) - Important Safety Information from Sanofi-Aventis Ireland Limited as approved by the HPRA

Notice type: 3rd Party Publications

Date: 28/01/2020

 


Problem Or Issue:

Important Safety Information from Sanofi-Aventis Ireland Limited regarding LEMTRADA (alemtuzumab) - Restricted indication, additional contraindications and risk minimisation measures

 

Important Safety Information - ­LEMTRADA (alemtuzumab)



« Back